|
|
Overexpression of MUC1 in prostate cancer has been associated with more aggressive disease. In this regard, MUC1 expression is detectable by immunohistochemical staining in ~90% of primary prostate cancers that were Gleason grade >7 or were metastatic to lymph nodes. Gene expression profiling has also shown that MUC1 is highly expressed in prostate cancers with aggressive clinicopathologic characteristics and an increased risk of disease recurrence.
Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, and Levine AC, MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol, 1999. 3:163-8.
Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, and Li Y, MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis, 2005. 22:565-73.
Arai T, Fujita K, Fujime M, and Irimura T, Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol, 2005. 12:654-61.
Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, and Mucci LA, MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer, 2007. 97:730-4.
Garbar C, Mascaux C, and Wespes E, Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: a preliminary study. Anal Quant Cytol Histol, 2008. 30:71-7.
Rabiau N, Dechelotte P, Guy L, Satih S, Bosviel R, Fontana L, Kemeny JL, Boiteux JP, Bignon YJ, and Bernard-Gallon D, Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo, 2009. 23:203-7.
Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, and Pollack JR, Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA, 2004. 101:811-6.
Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, and Li Y, MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis, 2005. 22:565-73.
Arai T, Fujita K, Fujime M, and Irimura T, Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol, 2005. 12:654-61.
Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, and Mucci LA, MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer, 2007. 97:730-4.
Garbar C, Mascaux C, and Wespes E, Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: a preliminary study. Anal Quant Cytol Histol, 2008. 30:71-7.
Rabiau N, Dechelotte P, Guy L, Satih S, Bosviel R, Fontana L, Kemeny JL, Boiteux JP, Bignon YJ, and Bernard-Gallon D, Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo, 2009. 23:203-7.
Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, and Pollack JR, Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA, 2004. 101:811-6.
